🔗 Share this article

Given that America undertakes unprecedented adjustments to its immunization guidelines, one figure has surfaced somewhat surprisingly: Høeg, a Danish American sports medicine doctor and epidemiologist who initially gained attention by questioning Covid vaccinations throughout the pandemic and has focused upon possible fatalities following COVID-19 vaccination in her recent position at the US Food and Drug Administration (FDA).

Planned Overhauls to Pediatric Vaccine Program

Agency leaders planned to reveal radical revisions to the pediatric vaccination calendar in December, synchronizing the US with Denmark’s vaccine program, sources say – a major change that would place the US out of alignment with a large portion of the international standard with little proof for public health gain. This reveal has been postponed until the new year.

Rather than the director of the vaccine center, Dr. Høeg is scheduled to address the audience at the event. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the division this calendar year.

A New Direction at the FDA

Høeg's temporary position might represent a tighter collaboration between the pharmaceutical and vaccine divisions as Dr. Høeg and Prasad solidify control at the FDA – and it suggests a greater focus upon dismantling long-standing immunizations at the FDA.

Høeg has frequently advocated for discontinuing some pediatric shot schedules in the US to become more in line with Denmark's approach, a society with comprehensive healthcare and a citizenry roughly the size of the state of Wisconsin.

In her initial statements, she has continued to focus on immunizations – usually the purview of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Questions Over Qualifications

Dr. Høeg has no apparent experience in drug development, oversight or management, which has been typical for former directors of the biologics center. She has served at the FDA as a senior adviser to the agency head and the vaccine center since March.

“She appears not to have the requisite experience” for running the pharmaceutical oversight division, remarked Jonathan Howard. “She has not conducted a scientific study. She has no expertise in leading a sizeable institution. She is not an expert in industry regulation.”

Past commissioners of CBER would “grasp legal statutes and the science of medication creation”, noted Dr. Janet Woodcock. “Frankly, she doesn’t have the kind of background that prior appointees who led CBER have had.”

CDER has an enormous range of responsibilities at the agency, she emphasized.

“Everybody just focuses on the novel medication approvals, but the generic program authorizes a multitude of generic drugs. There’s a biosimilars program, over-the-counter program and so forth, and each of these must be supervised,” Dr. Woodcock noted. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

There is also, a major leadership element to the role, which manages over 5,000 employees. “It is a massive leadership role, if you do it right,” the former official said.

Response and Disputed Initiatives

When asked about concerns about Høeg’s fitness for the role and whether this appointment indicates greater collaboration among FDA leaders on immunizations, a spokesperson said that the “concerns are based on flawed assumptions”.

“Her resume aligns with the functions of her job,” the representative stated, pointing to the period Dr. Høeg spent advising the FDA commissioner on “medication safety and oversight research, including computerized risk analysis and shot safety tracking”.

In her interim role, Høeg takes over the commissioner’s recently launched priority voucher program, a controversial one-day medication authorization process that apparently concerned her predecessors. “How are these therapies being picked for this expedited pathway? Who is making the choices?” Dr. Howard questioned. “There’s a lot of lack of transparency going on at the agency right now.”

In general, he stated, “the agency looks to be trending towards more relaxed rules of all drugs, with the exception of shots.”

Public Past Work on Immunizations

Regarding vaccines, Høeg has a clearer, if problematic, past, critics have noted. She released a study using unconfirmed crowd-sourced reports to estimate the incidence of myocarditis following COVID-19 immunization. She advised the state of Florida top health official Dr. Joseph Ladapo, who allegedly have changed statistics to suggest Covid vaccines are riskier than they are.

Among her “wish list” for the current government encompassed changing rules for new vaccines and ending “unnecessary” immunizations, she remarked following the vote on a online show. At the agency, Dr. Høeg has according to sources suggested barring young men from obtaining Covid vaccines.

“She’s an all-around dogmatist who commences with her beliefs and tailors the evidence to retrofit the evidence in a very deceptive, fraudulent way,” Dr. Howard stated.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg became part of fellow dissenters, {like|